TITLE:
Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

CONDITION:
Measles

INTERVENTION:
measles, mumps, and rubella virus vaccine live

SUMMARY:

      The purpose of this trial is to study the safety and immune response to measles, mumps, and
      rubella in children who were vaccinated with an investigational measles-mumps-rubella live
      vaccine made with artificially made human protein.
    

DETAILED DESCRIPTION:

      The duration of treatment is 6 weeks.
    

ELIGIBILITY:
Gender: All
Age: 12 Months to 18 Months
Criteria:

        Inclusion Criteria:

          -  Healthy children 12 to 18 months of age

        Exclusion Criteria:

          -  History or prior exposure to measles, mumps, or rubella

          -  History of allergic reactions to any component of the vaccines as evaluated by the
             study doctor
      
